World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
161
Citations
136886
World Ranking
734
National Ranking
417

Overview

Robert J. Motzer is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions to biochemistry, genetics, and molecular biology.

The main areas of study encompass pulmonary and respiratory medicine, oncology, molecular biology, cancer research, and economics and econometrics as applied to medical research.

Specific topics addressed in their work include:

  • Renal cell carcinoma treatment
  • Cancer immunotherapy and biomarkers
  • Renal and related cancers
  • Cancer genomics and diagnostics
  • Economic and financial impacts of cancer
  • Bladder and urothelial cancer treatments
  • Pancreatic and hepatic oncology research

Frequent coauthors in their publications include Toni K. Choueiri, Martin H. Voss, Ritesh R. Kotecha, Chung-Han Lee, and A. Ari Hakimi.

They have published extensively in several venues, with the most notable being:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Journal of Urology
  • European Urology
  • The Oncologist

Among their recent papers are:

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine
  • Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network

Other influential recent publications related to renal cell carcinoma and cancer treatment, although not authored by Robert J. Motzer but relevant in their field, include:

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma, 2021, New England Journal of Medicine
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

    Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;M. Dror Michaelson;Bruce G. Redman;Gary R. Hudes

  • Renal-cell carcinoma.

    Robert J. Motzer;Neil H. Bander;David M. Nanus

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma

    Robert J. Motzer;Madhu Mazumdar;Jennifer Bacik;William Berg

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

    Robert J. Motzer;Jennifer Bacik;Barbara A. Murphy;Paul Russo

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Testicular Germ-Cell Cancer

    George J. Bosl;Robert J. Motzer

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    Toni K. Choueiri;Thomas Powles;Mauricio Burotto;Bernard Escudier

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
George J. Bosl
George J. Bosl Memorial Sloan Kettering Cancer Center
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Paul Russo
Paul Russo Memorial Sloan Kettering Cancer Center
Thomas E. Hutson
Thomas E. Hutson Texas Oncology
Thomas Powles
Thomas Powles Queen Mary University of London
Victor E. Reuter
Victor E. Reuter Memorial Sloan Kettering Cancer Center
James J. Hsieh
James J. Hsieh Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open new doors within healthcare and adjacent fields. For aspiring nurses looking to advance their credentials efficiently, rn to np programs online offer a flexible route from registered nurse to nurse practitioner, often blending online coursework with required clinical hours.

Nutrition is another growing field for those interested in prevention and wellness. Accredited best online nutrition degree programs provide a solid foundation in nutritional science, helping graduates pursue roles as dietitians, wellness coaches, or public health educators.

For those drawn to healthcare leadership, online mha programs cahme accredited ensure quality education for future healthcare administrators. These degrees prepare students to manage hospitals, clinics, or healthcare systems with a focus on efficiency and patient care.

Registered nurses wanting to advance without in-person requirements can benefit from an rn to bsn without clinicals program. This pathway makes it easier to upgrade credentials while balancing work and other commitments.

Whether your passion is direct patient care, nutrition, or healthcare management, these online programs can support diverse career pathways in and around the field of medicine.

Best Scientists Citing Robert J. Motzer

Trending Scientists

Recently Published Articles